Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Paolo Ghia, Monika Dlugosz-Danecka, Lydia Scarfò & Wojciech Jurczak. (2021) Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. Leukemia & Lymphoma 62:5, pages 1066-1076.
Read now
Read now
Jon E Arnason & Jennifer R Brown. (2014) B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. ImmunoTargets and Therapy 3, pages 29-38.
Read now
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013)
Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now
Read now
Articles from other publishers (43)
Andrei A. Petrenko, Maria I. Kislova, Elena A. Dmitrieva & Eugene A. Nikitin. (2021) Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. Journal of Modern Oncology 23:2, pages 332-338.
Crossref
Crossref
Xianhui Wang, Leila Kokabee, Mostafa Kokabee & Douglas S. Conklin. (2021) Bruton’s Tyrosine Kinase and Its Isoforms in Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Alexey V. Danilov & Daniel O. Persky. (2020) Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. British Journal of Haematology 193:1, pages 15-25.
Crossref
Crossref
Xihui Chen, Fangfang Liu, Lijuan Yuan, Meng Zhang, Kun Chen & Yuanming Wu. (2020) Novel mutations in hyper‐IgM syndrome type 2 and X‐linked agammaglobulinemia detected in three patients with primary immunodeficiency disease. Molecular Genetics & Genomic Medicine 9:1.
Crossref
Crossref
Jizhen Liu, Musi Ji, Zhidong Li, Xun Xu, Lili Li, Huawen Li, Yuguang Tian & Xiaohua Su. (2020) A rapid UHPLC–MS/MS method for the quantification of ARQ531 in rat plasma: Validation and its application to a pharmacokinetic study. Biomedical Chromatography 34:11.
Crossref
Crossref
Alessandro Plebani & Vassilios Lougaris. 2020. Stiehm's Immune Deficiencies. Stiehm's Immune Deficiencies
443
466
.
Benjamin Martin James Shillitoe & Andrew R. Gennery. (2019) An update on X-Linked agammaglobulinaemia: clinical manifestations and management. Current Opinion in Allergy & Clinical Immunology 19:6, pages 571-577.
Crossref
Crossref
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli & Michele Cea. (2019) The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica 105:10, pages 2420-2431.
Crossref
Crossref
N. Wang, Y. Tian, S. Jia, L. Shao, W. Yu & M. Fang. (2019) A novel Bruton tyrosine kinase gene variation was found in an adult with X‐linked agammaglobulinemia during blood cross‐matching prior to surgical operation. Transfusion Medicine 29:5, pages 364-368.
Crossref
Crossref
Avick Kumar Ghosh, Indranil Samanta, Anushree Mondal & Wenshe Ray Liu. (2019) Covalent Inhibition in Drug Discovery. ChemMedChem 14:9, pages 889-906.
Crossref
Crossref
Dennis DobrovolskyEric S. WangSara Morrow, Catharine Leahy, Tyler FaustRadosław P. NowakKatherine A. DonovanGuang YangZhengnian LiEric S. FischerSteven P. Treon, David M. Weinstock & Nathanael S. Gray. (2019) Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood 133:9, pages 952-961.
Crossref
Crossref
Amene Saghazadeh & Nima Rezaei. 2019. Pulmonary Manifestations of Primary Immunodeficiency Diseases. Pulmonary Manifestations of Primary Immunodeficiency Diseases
77
120
.
Simar Pal Singh, Floris Dammeijer & Rudi W. Hendriks. (2018) Role of Bruton’s tyrosine kinase in B cells and malignancies. Molecular Cancer 17:1.
Crossref
Crossref
Yael Gernez, Mary Grace Baker & Paul J. Maglione. (2018) Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy. Transfusion 58:S3, pages 3056-3064.
Crossref
Crossref
M. V. Dybkov, Yu. S. Stepanovskyy, L. I. Chernyhova, A. P. Volokha, A. M. Hilfanova, A. V. Bondarenko, F. I. Lapiy, K. M. Dybkova & G. D. Telegeev. (2018) Molecular genetic test system for diagnosis of x-linked agammaglobulinemia. Faktori eksperimental'noi evolucii organizmiv 23, pages 186-191.
Crossref
Crossref
Xiao Liu, Tica Pichulik, Olaf-Oliver Wolz, Truong-Minh Dang, Andrea Stutz, Carly Dillen, Magno Delmiro Garcia, Helene Kraus, Sabine Dickhöfer, Ellen Daiber, Lisa Münzenmayer, Silke Wahl, Nikolaus Rieber, Jasmin Kümmerle-Deschner, Amir Yazdi, Mirita Franz-Wachtel, Boris Macek, Markus Radsak, Sebastian Vogel, Berit Schulte, Juliane Sarah Walz, Dominik Hartl, Eicke Latz, Stephan Stilgenbauer, Bodo Grimbacher, Lloyd Miller, Cornelia Brunner, Christiane Wolz & Alexander N.R. Weber. (2017) Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. Journal of Allergy and Clinical Immunology 140:4, pages 1054-1067.e10.
Crossref
Crossref
Sarah E.M. Herman, Arnau Montraveta, Carsten U. Niemann, Helena Mora-Jensen, Michael Gulrajani, Fanny Krantz, Rose Mantel, Lisa L. Smith, Fabienne McClanahan, Bonnie K. Harrington, Dolors Colomer, Todd Covey, John C. Byrd, Raquel Izumi, Allard Kaptein, Roger Ulrich, Amy J. Johnson, Brian J. Lannutti, Adrian Wiestner & Jennifer A. Woyach. (2017) The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research 23:11, pages 2831-2841.
Crossref
Crossref
Hyebin Park, Chi Hoon Park, Seung-Tae Kang, Jeong Hee Jeon, Raghavendra Archary, Joo-Youn Lee, Pilho Kim, Heejung Jung, Chang-Soo Yun, Jong Yeon Hwang, Do Hyun Ryu & Sung Yun Cho. (2017)
Design and Synthesis of Novel Pyrazolo[3,4-
d
]pyrimidin-1-yl piperidine Derivatives as Bruton's Tyrosine Kinase Inhibitors
. Bulletin of the Korean Chemical Society 38:2, pages 278-281.
Crossref
Crossref
T.G. Murali Dhar & A.J. Dyckman. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
395
419
.
Scott H. Watterson, George V. De Lucca, Qing Shi, Charles M. Langevine, Qingjie Liu, Douglas G. Batt, Myra Beaudoin Bertrand, Hua Gong, Jun Dai, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Chunlei Wang, Yingru Zhang, Sarah C. Traeger, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Yifan Zhang, Elizabeth Heimrich, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Michael A. Galella, Andy J. Tebben, Jodi K. Muckelbauer, ChiehYing Chang, Richard Rampulla, Arvind Mathur, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke & Joseph A. Tino. (2016)
Discovery of 6-Fluoro-5-(
R
)-(3-(
S
)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4
H
)-yl)-2-methylphenyl)-2-(
S
)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1
H
-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers
. Journal of Medicinal Chemistry 59:19, pages 9173-9200.
Crossref
Crossref
George V. De Lucca, Qing Shi, Qingjie Liu, Douglas G. Batt, Myra Beaudoin Bertrand, Rick Rampulla, Arvind Mathur, Lorell Discenza, Celia D’Arienzo, Jun Dai, Mary Obermeier, Rodney Vickery, Yingru Zhang, Zheng Yang, Punit Marathe, Andrew J. Tebben, Jodi K. Muckelbauer, ChiehYing J. Chang, Huiping Zhang, Kathleen Gillooly, Tracy Taylor, Mark A. Pattoli, Stacey Skala, Daniel W. Kukral, Kim W. McIntyre, Luisa Salter-Cid, Aberra Fura, James R. Burke, Joel C. Barrish, Percy H. Carter & Joseph A. Tino. (2016)
Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9
H
-carbazole-1-carboxamide (BMS-935177)
. Journal of Medicinal Chemistry 59:17, pages 7915-7935.
Crossref
Crossref
Odilia B. J. Corneth, Marjolein J. W. de Bruijn, Jasper Rip, Patrick S. Asmawidjaja, Laurens P. Kil & Rudi W. Hendriks. (2016) Enhanced Expression of Bruton’s Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis. The Journal of Immunology 197:1, pages 58-67.
Crossref
Crossref
John C Allen, Fatima Talab & Joseph R Slupsky. (2016) Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?. International Journal of Hematologic Oncology 5:1, pages 37-53.
Crossref
Crossref
Ogunleye Foluso, Alexander Glick, Michael Stender & Ishmael Jaiyesimi. (2016) Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise. Clinical Lymphoma Myeloma and Leukemia 16:2, pages 63-69.
Crossref
Crossref
Harriet S. Walter, Simon A. RuleMartin J. S. Dyer, Lionel KarlinCeri JonesBruno CazinPhilippe QuittetNimish ShahClaire V. HutchinsonHideyuki Honda, Kevin Duffy, Joseph Birkett, Virginia Jamieson, Nigel Courtenay-Luck, Toshio Yoshizawa, John Sharpe, Tomoya Ohno, Shinichiro Abe, Akihisa Nishimura, Guillaume CartronFranck MorschhauserChristopher FeganGilles Salles. (2016) A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 127:4, pages 411-419.
Crossref
Crossref
G. Elizabeth Legger, Nico M. Wulffraat & Joris M. van Montfrans. 2016. Textbook of Pediatric Rheumatology. Textbook of Pediatric Rheumatology
597
608.e5
.
Kamil Bojarczuk, Malgorzata Bobrowicz, Michal Dwojak, Nina Miazek, Piotr Zapala, Anders Bunes, Marta Siernicka, Maria Rozanska & Magdalena Winiarska. (2015) B-cell receptor signaling in the pathogenesis of lymphoid malignancies. Blood Cells, Molecules, and Diseases 55:3, pages 255-265.
Crossref
Crossref
Burcu Bestas, Janne J. Turunen, K. Emelie M. Blomberg, Qing Wang, Robert Månsson, Samir EL Andaloussi, Anna Berglöf & C. I. Edvard Smith. (2015) Splice-Correction Strategies for Treatment of X-Linked Agammaglobulinemia. Current Allergy and Asthma Reports 15:3.
Crossref
Crossref
Odilia B. J. Corneth, Roel G. J. Klein Wolterink & Rudi W. Hendriks. 2016. B Cell Receptor Signaling. B Cell Receptor Signaling
67
105
.
Adrian Wiestner. (2014) BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology 2014:1, pages 125-134.
Crossref
Crossref
Bixia Zheng, Yayuan Zhang, Yu Jin & Haiguo Yu. (2014) A novel Bruton’s tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia. BMC Pediatrics 14:1.
Crossref
Crossref
Ger T. Rijkers, Jan G.M.C. Damoiseaux & Herbert Hooijkaas. (2014) Medical immunology: Two-way bridge connecting bench and bedside. Immunology Letters 162:2, pages 127-133.
Crossref
Crossref
Natthakorn Rattanachartnarong, Siraprapa Tongkobpetch, Pantipa Chatchatee, Tassalapa Daengsuwan, Chupong Ittiwut, Kanya Suphapeetiporn & Vorasuk Shotelersuk. (2014) In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides. Archivum Immunologiae et Therapiae Experimentalis 62:5, pages 431-436.
Crossref
Crossref
Emma Slack, Maria L. Balmer & Andrew J. Macpherson. (2014) B cells as a critical node in the microbiota-host immune system network. Immunological Reviews 260:1, pages 50-66.
Crossref
Crossref
Rudi W. Hendriks, Saravanan Yuvaraj & Laurens P. Kil. (2014) Targeting Bruton's tyrosine kinase in B cell malignancies. Nature Reviews Cancer 14:4, pages 219-232.
Crossref
Crossref
Artemio M. Jongco, Jonathan D. Gough, Kyle Sarnataro, David W. Rosenthal, Joanne Moreau, Punita Ponda & Vincent R. Bonagura. (2014) X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii. Annals of Allergy, Asthma & Immunology 112:1, pages 74-75.e2.
Crossref
Crossref
Alessandro Plebani & Vassilios Lougaris. 2014. Stiehm's Immune Deficiencies. Stiehm's Immune Deficiencies
329
346
.
Carsten U. Niemann & Adrian Wiestner. (2013) B-cell receptor signaling as a driver of lymphoma development and evolution. Seminars in Cancer Biology 23:6, pages 410-421.
Crossref
Crossref
Jennifer R. Brown. (2013) Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials. Current Hematologic Malignancy Reports 8:1, pages 1-6.
Crossref
Crossref
Adrian Wiestner. (2013) Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies. Journal of Clinical Oncology 31:1, pages 128-130.
Crossref
Crossref
Carsten U. Niemann, Jade Jones & Adrian Wiestner. 2013. Advances in Chronic Lymphocytic Leukemia. Advances in Chronic Lymphocytic Leukemia
259
291
.
Laurens P. KilMarjolein J. W. de BruijnMenno van NimwegenOdilia B. J. CornethJan Piet van HamburgGemma M. DingjanFriedrich ThaissGuus F. RimmelzwaanDirk Elewaut, Dianne Delsing, Pieter Fokko van LooRudi W. Hendriks. (2012) Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119:16, pages 3744-3756.
Crossref
Crossref
Miriam Hoernes, Reinhard Seger & Janine Reichenbach. (2011) Modern management of primary B-cell immunodeficiencies. Pediatric Allergy and Immunology 22:8, pages 758-769.
Crossref
Crossref